The Next Vioxx – The Next
FDA Cover Up
By: Shane Ellison, M.Sc.
Copyright 2004 All Rights Reserved
That Vioxx™ (rofecoxib), a cyclo-oxygenase-2 (COX 2) inhibitor,
causes increased heart attack and stroke among users was known 4
years prior to its removal from the corporate drug market. This
fact is substantiated by the study known as VIGOR (VIOXX
Gastrointestinal Outcomes Research), performed in 2000 by MERCK.
VIGOR showed that the COX-2 inhibitor promotes the clotting of
blood and high blood pressure due to sodium retention in the
kidney in some users. The "deadly duo" elicited an estimated
100,000 preventable injuries in Vioxx™ users. The grotesque
imitation of what should be the scientific community is not
stopping what appears to be the next "FDA cover up."
A member of the FDA's drug safety advisory committee and a
well-known authority on drug safety, Dr. Curt Furberg, recently
came forward to announce that Bextra ™ (valdecoxib), a chemical
cousin of Vioxx™, also causes heart attack and stroke. Published
by the British Medical Journal (BMJ), Dr. Furberg insists that
his studies "Showed that Bextra is no different than Vioxx, and
Pfizer is trying to suppress that information." Immediately
thereafter, Dr. Furberg was barred from serving on the panel
that is responsible for considering the safety of
cyclo-oxygenase-2 (COX 2) inhibitors.(1)
Dr. Furberg is not alone in his convictions. Garret Fitzgerald,
MD, PharmD, of the Center for Experimental Therapeutics,
University of Pennsylvania, Philadelphia, discussed his findings
relative to Bextra ™ at the American Heart Association
Scientific Session 2004 on November 10th. His studies showed
that the risk for heart attack and stroke was more than twice as
high among those patients taking Bextra™ compared to the placebo
group.(2) These were identical to the findings of Vioxx™ in the
As chemical cousins, Vioxx™ and Bextra™ share the same
biochemical qualities. Both drugs are considered COX 2
inhibitors. Both drugs thicken the blood. Just like concrete
thickens upon addition of water, so does the blood upon addition
of Bextra™. Technically speaking, both COX 2 inhibitors increase
the production of thromboxane.(3) This chemical promotes blood
clotting, which in turn increases the chances of suffering from
heart attack and stroke.
Pfizer and the FDA aren't letting this out, even if it means
barring leading scientists from advisory boards. This approach
works because pharmaceutically-complaint politicians have
democratized the drug industry. Drug safety is a simple matter
of 51% telling the other 49% that deadly drugs like Bextra™ are
safe and necessary.
Science and choice no longer prevail in medicine. Instead,
health tyranny, motivated by profit and asserted by insurance
companies, dominates. Rent-a-quote medical doctors simply follow
orders by mandating prescription drug addiction. This is so
apparent that it would take a highly educated person to miss it.
Health is only guaranteed to those who resist the greed-driven
current that draws them to deadly, FDA approved drugs.
About the Author
Shane holds a Master's degree in organic chemistry and has
first-hand industry experience with drug research, design and
synthesis. He understands that Americans want and deserve
education rather than prescriptions. His shocking ebook
surrounding cholesterol lowering drugs can be downloaded for
FREE as a pdf file at www.health-fx.net/eBook.pdf. His book
Health Myths Exposed is available at
1. Lenzer, Jeanne. FDA bars own expert from evaluating risks of
painkillers. British Medical Journal 2004;329:1203 (20 November)
2. Laino, Charlene. AHA: Valdecoxib Linked to Cardiovascular
3. Ouellet, Marc, Riendeau, Denis, and Percival, M. David. A
high level of cyclooxygenase-2 inhibitor selectivity is
associated with a reduced interference of platelet
cyclooxygenase-1 inactivation by aspirin. Proc. Natl. Acad. Sci.
U. S. A. 98 (2001): 14583-88.